Barclays lowered the firm’s price target on Certara (CERT) to $12 from $14 and keeps an Equal Weight rating on the shares. The firm says Certara continued to make progress on its Cloud platform as it builds a full suite of Software offerings across the clinical trial continuum, streamlining its offerings.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.